Cure My Disease

Don't miss your cure!

 Log in / Sign up

Generic selegiline patch put to the test in healthy volunteers

NCT ID NCT07571824

Completed Knowledge-focused Sponsor: Corium Innovations, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study compares a new generic selegiline skin patch to the brand-name EMSAM® patch in 92 healthy adults. Researchers measure how much drug enters the bloodstream and how well the patch sticks to the skin over 24 hours. The goal is to see if the generic version works just as well as the original.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
selegiline transdermal patch
What this could lead to
If successful, this could lead to a lower-cost generic version of the selegiline patch for treating depression or Parkinson's disease.
What could go wrong
This is an early-phase study in healthy volunteers, not patients. It only checks if the generic patch delivers the same drug dose and sticks well—it does not test effectiveness for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULT PARTICIPANTS

Contacts and locations

Locations

  • Novum Pharmaceutical Research Services

    Las Vegas, Nevada, 89121, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.